Replies to post #1176 on IDM Pharma, Inc. (IDMI)

[meixatech]

Bow,

I was concerned also. The board approved Walbert’s dual roll, apparently with no dissent. I got this impression during the SHM. I also got the impression, with no uncertain terms expressed at the SHM, that the IDMI is all but sold – I do not believe that the final value of the sale depends on approval of L-MPT-PE by the EMEA. The announcement of the sale may well happen prior to the EMEA approval. One of the directors did agree with me when I stated that the real value of such a deal would be IDM-2101. Think about it. L-MPT-PE is small potatoes for a BP or large biotech - it is the pipeline where the value of IDMI lies.

Walbert’s new CEO position would not have been approved if the board thought that IDMI would be going into the actual marketing of L-MPT-PE. If that were the case, Walbert would have resigned for the new position.

[tzm]

My take on things is that Walbert is a hired gun who was brought on to straighten out the applications. He has done an incredible job so far and he will become legendary in the biotech world when he gets MTP approved. The key to his accomplishments at IDM was getting the COG to do a 180 and to completely support IDM.

Walbert has over 500K shares in stock options that range from zero to three dollars and so his payday is tied to the stock.

http://www.secform4.com/insider-trading/822206.htm